Table 2

Treatment discontinuation and dosing information at 8-month follow-up

Efficacy cohortMBC-CMLLBC-CML
No. patients 74 42 
Still on treatment, no. (%) 23 (31) 5 (12) 
Discontinued study therapy, no. (%) 51 (69) 37 (88) 
    Disease progression 25 (34) 22 (52) 
    Study drug toxicity 8 (11) 1 (2) 
    AE unrelated to study drug 2 (3) 0 (0) 
    Death 7 (9) 6 (14) 
    Noncompliance 1 (1) 0 (0) 
    Deterioration without progression 2 (3) 3 (7) 
    Other 6 (8) 5 (12) 
Median duration of dasatinib therapy, mo (range)   
    Total treated population 3.5 (0.03-12.0) 2.8 (0.1-9.2) 
    Population still on study 9.2 (7.8-12.0) 8.3 (7.6-9.2) 
Median of average daily dasatinib dose, mg/d 137.0 140.0 
Efficacy cohortMBC-CMLLBC-CML
No. patients 74 42 
Still on treatment, no. (%) 23 (31) 5 (12) 
Discontinued study therapy, no. (%) 51 (69) 37 (88) 
    Disease progression 25 (34) 22 (52) 
    Study drug toxicity 8 (11) 1 (2) 
    AE unrelated to study drug 2 (3) 0 (0) 
    Death 7 (9) 6 (14) 
    Noncompliance 1 (1) 0 (0) 
    Deterioration without progression 2 (3) 3 (7) 
    Other 6 (8) 5 (12) 
Median duration of dasatinib therapy, mo (range)   
    Total treated population 3.5 (0.03-12.0) 2.8 (0.1-9.2) 
    Population still on study 9.2 (7.8-12.0) 8.3 (7.6-9.2) 
Median of average daily dasatinib dose, mg/d 137.0 140.0 

or Create an Account

Close Modal
Close Modal